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Abstract
Activating enhancer-binding protein 2; (AP-2;) is a
member of the developmentally regulated AP-2 tran-
scription factor family that regulates the expression of
many downstream genes.Whereas the effects of AP-2A
overexpression on cell growth are fairly well estab-
lished, the cellular effects of AP-2; overexpression are
less well studied. Our new findings show that AP-2;
significantly upregulates p21 mRNA and proteins, in-
hibits cell growth, and decreases clonogenic survival.
Cell cycle analysis revealed that forced AP-2; expres-
sion induced G1-phase arrest, decreased DNA syn-
thesis, and decreased the fraction of cells in S phase.
AP-2; expression also led to cyclin D1 repression,
decreased Rb phosphorylation, and decreased E2F ac-
tivity in breast carcinoma cells. AP-2; binding to the
p21 promoter was observed in vivo, and the absence of
growth inhibition in response to AP-2; expression in
p21 (/) cells demonstrated that p21 caused, at least in
part, AP-2–induced cell cycle arrest. Finally, the tumor
growth of human breast carcinoma cells in vivo was
inhibited by the expression of AP-2; relative to empty
vector–infected cells, suggesting that AP-2; acts as a
tumor suppressor. In summary, expression of either
AP-2; or AP-2A inhibited breast carcinoma cell growth;
thus, these genes may be therapeutic targets for
breast cancer.
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Introduction
The family of activating enhancer-binding protein 2 (AP-2)
transcription factors consists of five different genes: AP-2a
[1,2], AP-2 [3], AP-2c [4], AP-2d [5], and AP-2e [6]. All
AP-2 family members share a high homology and simi-
lar multidomain structures consisting of a less-conserved
proline-rich transactivation domain, a highly conserved
basic helical DNA-binding domain, and a dimerization do-
main, allowing them to form homodimers and heterodimers
[7]. Among various family members, AP-2a has been more
extensively studied than the others. AP-2a is a retinoic
acid– inducible transcription factor that participates in the
proper development of the eyes, face, limbs, body wall, and
neural crest [8–10]. Both AP-2a and AP-2g are required in
early embryonic development and are involved in proliferation
and differentiation [11,12].
AP-2a–regulated genes are involved in many important
biologic functions and include genes such as c-kit [13],
MUC18 [14], MMP-2 [15], and KAI1 [16]. AP-2g has been re-
ported to participate in the regulation of ErbB2 and estrogen
receptor (ER) a, both of which are implicated in breast cancer
initiation and progression [17–19]. AP-2a overexpression can
reduce thymidine synthesis and BrdU incorporation, and can
induce hypophosphorylated Rb and the universal cell cycle
inhibitor, p21WAF1/CIP1 [20]. In addition to arresting cell cycle
progression, AP-2a was found to induce programmed cell
death, and both AP-2a and AP-2g are susceptible to caspase
3 cleavage [20,21]. The AP-2a protein can physically and func-
tionally interact with many other proteins, including p53 [22],
retinoblastoma protein (pRb) [23], c-Myc [24], and SV40 large T
antigen [1]. Although fewer such studies have been performed
on AP-2g to date, it has been demonstrated to bind p53 in a
manner similar to that previously described for AP-2a [22].
As mentioned above, AP-2a and AP-2g are associated with
the expression of ERa and ErbB-2 in breast cancer, both of
which can promote tumorigenesis and metastasis [17]. By con-
trast, AP-2a appears to display tumor-suppressor activity in
breast cancer cells, melanoma cells, and prostate cancer cells
[13,14,25]. Vascular endothelial growth factor, an angiogenic
factor in cancer development, was found to be deregulated
after AP-2a expression [25]. Ametastasis inhibitor, KiSS-1, was
also demonstrated to be induced by AP-2a in breast cancer
cell lines [26]. Low nuclear AP-2a expression in human breast
cancer was found to be associated with disease progression
and an increased metastatic capability of the tumor [27]. Re-
duced nuclear AP-2 expression was also demonstrated to
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independently predict an elevated risk of recurrent disease
in breast cancer [28]. Additionally, AP-2a is a target of DNA
methylation–mediated silencing in human breast cancer
cells [29], whereas AP-2g is reported to be a marker of germ
cell tumors [30,31]. A recent study [32] revealed that there is
a dual role for AP-2g in different mammary tumorigenic
stages: inhibition of tumor initiation and promotion of prolif-
eration. Taken together, these findings provide evidence that
AP-2 participates in a complex biologic dynamics, including
cell cycle progression, apoptosis, and tumor formation.
The tumor-suppressor activity of AP-2a was shown by
demonstrating that its forced expression led to decreased
cancer cell growth in vivo and in vitro [15,20]. Because
AP-2a and AP-2g share a high homology and certain com-
mon biologic functions, including heterodimer formation, it is
of considerable interest to determine whether AP-2g acts
in a manner similar to that of AP-2a regarding cell growth
regulation. Thus, we performed experiments to determine
whether AP-2g may similarly act as a tumor suppressor in
human carcinoma cells.
Our data compared AP-2a and AP-2g in several aspects
related to human cancer cell growth. We used recombinant
adenoviruses Ad-AP-2a and Ad-AP-2g to elevate wild-type
(wt) AP-2a and AP-2g expression, respectively, and mea-
sured the effects of forced AP-2 expression in human carci-
noma cells. Our results indicated that wt AP-2a or AP-2g
overexpression inhibited MDA MB-231 cell growth, de-
creased clonogenic survival, and arrested cell cycle progres-
sion. Both AP-2a and AP-2g induced p21 mRNA and protein
to the same level within 24 hours of adenovirus infection.
Similar effects on cyclin D1, E2F, and Rb phosphorylation
were observed in both treatments. AP-2a and Ad-AP-2g
share the same DNA consensus-binding site; thus, it may
not be surprising that AP-2g was enriched at the AP-2–
binding sites in the p21 promoter [33]. Taken together, these
findings strongly suggest that these two AP-2 family members
perform their functions through similar pathways, perhaps
even working in concert. The failure of Ad-AP-2 expression
to arrest cell cycle in p21 knockout cells revealed the impor-
tance of p21 in both AP-2a– and AP-2g–induced cell cycle
arrests. In our in vivo animal experiments, both AP-2a and
AP-2g significantly decreased MDA MB-231 tumorigenicity
and inhibited tumor growth in nude mice. Thus, AP-2 may
function as a tumor suppressor in human breast cancer.
Materials and Methods
Cell Culture
MDA MB-231 human breast adenocarcinoma cells were
obtained from the American Type Culture Collection (Rock-
ville, MD). They were routinely cultured in RPMI 1640 me-
dium. HCT116 parental and p21 (/) cells (kindly provided
by Dr. Bert Volgestein) were kept in Dulbecco’s modified
Eagle’s medium. All media were supplemented with 10%
fetal bovine serum and 50 mg/ml penicillin/streptomycin.
Cells were incubated at 37jC with 95% air and 5% CO2.
The medium was changed every 3 to 4 days.
Adenovirus Constructs
AP-2a cDNA (provided by Dr. Trevor Williams [2]) was
subcloned into a pcDNA3 mammalian expression vector
(Invitrogen, Carlsbad, CA). The AP-2g expression vector
AP-2g pcDNA3 was generously provided by Dr. Ronald J.
Weigel [19]. Ad-AP-2a and Ad-AP-2g adenoviruses were
produced at the University of Iowa’s Gene Transfer Vector
Core Facility. The corresponding vector control was Ad-Bgl II,
which contains only the adenovirus backbone. All adeno-
virus stocks were maintained at the University of Iowa’s
Vector Core Facility, where infectious particles were also
amplified, purified, and characterized.
Clonogenic Survival Assay
We infected MDA MB-231 cells with 100 multiplicity of
infection (MOI) of Ad-Bgl II, Ad-AP-2a, or Ad-AP-2g. Twenty-
four hours after infection, the total number of cells was de-
termined using a Coulter counter (Beckman Coulter, Inc.,
Fullerton, CA). The number of cells plated into each cell cul-
ture dish was adjusted to give about 50 to 100 surviving col-
onies per dish. The cells were incubated at 37jC for 14 days
to form colonies. The colonies were then fixed and stained
by gentle addition of crystal violet to the medium in the cell
culture dish. Colonies containing more than 50 cells were
counted as surviving clonogenic cells, and the surviving frac-
tion was normalized to the plating efficiency, as given below
Plating efficiency ðPEÞ ¼ colonies formed
untreated cells seeded
Surviving efficiency ðSEÞ ¼ colonies formed
number of cells seeded PE
:
Nuclear Protein Extraction
Nuclear extracts were prepared according to the method
of Zhu et al. [34], as previously described. Briefly, themedium
was removed from tissue culture dishes. Cells were washed
twice with phosphate-buffered saline (PBS) and scrape-
harvested in 500 ml of ice-cold hypotonic buffer (10 mM
HEPES, 1.5 mMMgCl2, 10 mM KCl, and 0.5 mM DTT). Cells
were incubated on ice for 20minutes, lysed by a glass dounce
homogenizer with type B pestle, and centrifuged at 300g
for 5 minutes. Supernatants were saved as cytosolic pro-
teins, and 40 ml of ice-cold high-salt buffer (20 mM HEPES,
25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM PMSF, and 0.5 mM DTT) was added to the nuclear
pellets and mixed. The nuclei were incubated on ice for
15 minutes and centrifuged at maximum speed for 1 minute.
Supernatants were saved as nuclear protein extracts. Pro-
tein concentrationswere determinedwith Bio-RadDCprotein
assay (Bio-Rad Laboratories, Hercules, CA), according to
the manufacturer’s instructions.
Total Protein Extraction
Cells were collected by trypsinization and centrifugation
and incubated in RIPA buffer [150 mM NaCl; 50 mM Tris,
pH 8.0; 1 mM EDTA; 0.5% NP40; 0.1 mM Na3VO4; 1% so-
dium deoxycholic acid; and 0.1% sodium dodecyl sulfate
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(SDS)] for 30 minutes on ice. After 15 seconds of sonication,
cell lysates were centrifuged for 1 minute at 13,000 rpm.
Supernatants were saved as total protein extracts.
Western Blot Analysis
Equal amounts of proteins from differently treated cells
were size-fractionated on a 10% (pRb) or a 12% (all other
proteins) Tris–HCl polyacrylamide ready gel (Bio-Rad Labo-
ratories). Separated proteins were then electrotransferred
to a nitrocellulose membrane (Schleicher and Schuell, Keene,
NH) by running at 100V for 1 hour (6 hours for pRb). For AP-2a
and AP-2g Western blot analyses, the primary antibodies
were mouse anti–AP-2a IgG and mouse anti–AP-2g-IgG, re-
spectively (Santa Cruz Biotechnology, Santa Cruz, CA), both
used at 1:400 dilution. For p21 Western blot analyses, the
primary antibody was mouse anti-p21 IgG (Pharmingen, San
Diego, CA), used at a dilution of 1:250. For phospho-
Rb (pS780) Western blot analyses, the primary antibody
was rabbit anti-pRb (pS780) IgG (Cell Signaling Technology,
Beverly, MA), used at a dilution of 1:1000. For cyclin D1
Western blot analyses, the primary antibody was mouse
anti–cyclin D1 IgG (Pharmingen), used at a dilution of
1:1500. For b-actin Western blot analyses, the primary anti-
body was mouse anti–human b-actin IgG (Santa Cruz Bio-
technology), used at a dilution of 1:3000. For AP-2, cyclin D1,
and actin Western blot analyses, the secondary antibody was
goat anti-mouse IgG (Pharmingen), used at a 1:10,000 dilu-
tion. For p21 and pRb (pS780), the secondary antibody was
used at 1:3000 dilution. Blots were washed with TTBS (0.02M
Tris–HCl buffer, pH 7.5; 0.137 M NaCl; and 0.1% Tween 20).
Detection by chemiluminescence reaction was carried out
using an enhanced chemiluminescence kit (Amersham Phar-
macia Biotech, Piscataway, NJ), followed by exposure to
Kodak X-ray film (Kodak, Rochester, NY).
Electrophoretic Gel Mobility Shift Assay (EMSA)
We used double-stranded oligodeoxynucleotides con-
taining a consensus AP-2–binding sequence (Promega,
Madison, WI). The probe was made by labeling these
double-stranded oligonucleotides with [g-32P] ATP using T4
polynucleotide kinase. After that, 10 mg of nuclear protein
was incubated with the 32P-radiolabeled oligonucleotide
probe in the presence of 1 mg of poly(dIdC) (Amersham Phar-
macia Biotech) and 1 gel shift buffer (10 mM Tris, pH 7.5;
50 mM NaCl; 1 mM MgCl2; 0.5 mM EDTA; 0.5 mM di-
thiothreitol; and 4% glycerol) at room temperature for
20 minutes. Binding reactions were loaded onto a 5% poly-
acrylamide gel and run at 100 V in 1 TBE (90 mM Tris,
90 mM boric acid, and 2 mM EDTA, pH 8.0). The gels were
wrapped in plastic wrap and exposed to Kodak X-ray film
overnight at 80jC. To assess the specificity of the binding
reaction, antibodies specific to AP-2a and AP-2g were in-
cubated with each binding reaction for 20 minutes before
loading onto the gel.
Plasmid Constructs and Reporter Gene Assays
An E2F-responsive reporter construct, pE2F-Luc (Clon-
tech, Mountain View, CA), containing four E2F consensus-
binding sites in the enhancer region upstream of the firefly
luciferase genewas used to characterize E2F-transactivating
activity in cells expressing AP-2. Firefly luciferase activities
were determined using the Dual Luciferase assay system
(Promega) and were normalized relative to renilla luciferase
activity. Reproducibility was ensured by transfection per-
formed in triplicate.
Cell Cycle Analysis
Cells were plated at 5 105 cells/dish and infectedwith 100
MOI of various adenoviruses for 24 hours. After 24-hour
infection, the medium was changed, and cells were pulse-
labeled with BrdU (final concentration, 1 mM) for 30 minutes.
Cells were washed with 1 PBS and fixed with 70% cold
ethanol. Cells were washed with PBT (1 PBS, 1 mg/ml BSA,
and 0.1% Tween 20) on the next day and digested with pep-
sin for half an hour. After neutralization with 0.1 M borax,
nuclei were washed again and incubated with BrdU pri-
mary antibody (Becton Dickinson Immunocytometry Systems,
San Jose, CA) and fluorescein isothiocyanate (FITC) GAM
secondary antibody (Becton Dickinson), following the manu-
facturer’s protocol. Sampleswereanalyzedat theFlowCytom-
etry Facility at the University of Iowa. Data were analyzed
with CellQuest software (Becton Dickinson) for combined
BrdU/propidium iodide (PI) staining, and with ModFit software
(Verity Software House, Topsham, ME) for PI staining only.
Real-Time Reverse Transcription–Polymerase Chain
Reaction (RT-PCR) Analysis
Total RNA was extracted using Qiagen RNeasy kit
(Qiagen, Inc., Valencia, CA). RT was performed using high-
capacity cDNA archive kit (Applied Biosystems, Foster City,
CA), according to the manufacturer’s protocol. PCR con-
ditions were as follows: 95jC for 10 minutes, followed by
40 cycles of denaturation at 95jC for 30 seconds, and
annealing and extension at 60jC for 1.5 minutes. PCR was
performed, and data were collected using the ABI Prism
7000 real-time sequence detection system (Applied Bio-
systems). The target gene was detected using SYBR green
PCR master mix (Applied Biosystems). Differences in ex-
pression were determined using relative quantity calculated
by standard curve. p21mRNA level was determined bySYBR
Green master mix (Applied Biosystems) using forward
primer 5V-ATCCCGTGTTCTCCTTT and reverse primer 5V-
GCTGGCATGAAGCC. Cyclin D1 was detected by using the
forward primer 5V-GAGGTCTGCGAGGAACAGAAGT and
the reverse primer 5V-CCTTCATCTTAGAGGCCACGA.
Chromatin Immunoprecipitation (ChIP) Assays
MDA MB-231 cells were infected with 100 MOI of Ad-Bgl
II, Ad-AP-2a, or Ad-AP-2g for 24 hours. Cells were treated
with 1% formaldehyde for 10 minutes. The cells were then
gently scraped and collected by centrifugation at 4jC. Cells
pellets were resuspended in 500 ml of sonication buffer
(50 mM Tris–Cl, pH 8.0; 10 mM EDTA; 1% SDS; and pro-
teinase inhibitors) and incubated on ice for 10minutes. DNA–
protein complexes were sonicated to lengths between 200
and 1000 bp, as determined by gel electrophoresis. Samples
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were centrifuged at 16,000g at 4jC to spin out cell debris, and
then the supernatant was diluted 10-fold with ChIP dilution
buffer. One tenth of the samplewas set aside for input control,
and the remaining sample was precleared with protein A/G
PLUS Agarose (Upstate Biotech, Charlottesville, VA). Fol-
lowing preclearing, the sample was split in half and the two
portions were incubated with 30 ml of anti–AP-2a antibody
(Santa Cruz Biotechnology) and 30 ml of anti–AP-2g antibody
(Santa Cruz Biotechnology), respectively, plus protein A/G
PLUS agarose. Following overnight incubation at 4jC, the
beads were washed with low-salt, high-salt, and LiCl wash
buffers, and then twice with Tris–EDTA, pH 8.0. Chromatin–
antibody complexes were eluted, and DNA–protein cross-
links were reversed with 0.4 M NaCl (final concentration)
at 65jC for 4 hours. Samples were subsequently treated
with proteinase K, and genomic DNA was recovered by
Qiagen DNeasy kit (Qiagen, Inc.) and quantitated with a Bio-
Photometer (Eppendorf Scientific, Hamburg, Germany).
Conventional genomic PCR was used to analyze ChIP
DNA using PCR Master Mix (Qiagen, Inc.) following manu-
facturer’s protocol (20% Q-solution was added). PCR was
carried out on 70 ng of ChIP DNA using the following con-
ditions: 95jC for 15 minutes, 94jC for 30 seconds, 57jC for
30 seconds, and 72jC for 30 seconds (40 cycles in total). The
corresponding PCR primers used were as follows: p21 for-
ward primer 5V-GCCAGATTTGTGGCTCACTTCG and p21
reverse primer 5V-ACGCTTGGCTCGGCTCTGG.
In Vivo Tumorigenicity Assays
All animal experiments were conducted in strict accor-
dance with an approved IACUC protocol from the Office of
Animal Research at the University of Iowa. Athymic nude
mice were housed in specific pathogen-free conditions at the
animal care facility at the University of Iowa. Under sterile
conditions in a laminar flow hood, 7- to 8-week-old female
nude mice were injected subcutaneously with 5  106 MDA
MB-231 cells into each flank. The animals were examined
every 4 days for the status of tumor growth. Tumor sizes
(Tumor volume = length width height / 2) were measured
as a function of time. Animals were sacrificed when any
tumor reached 1 cm3. To determine the tumorigenic capability
of differently treated cells, MDA MB-231 cells were infected
with 100 MOI of vector control or Ad-AP-2 for 24 hours be-
fore injection into mice. To infect established tumors in mice,
1  109 pfu of adenoviruses was injected into each tumor
when the average diameter was 3 to 4 mm. Animals were
grouped at the beginning to achieve the same average tumor
volume within each group. Adenoviral injections were per-
formed every 5 days (a total of three times).
Results
Forced Expression of Either AP-2a or AP-2c Caused
Increased AP-2 DNA-Binding Activity and Decreased
Clonogenic Survival
Some experimental evidence has suggested that AP-2a
is able to inhibit tumor cell growth and thus is a possible
tumor suppressor [13,15]. We selected MDA MB-231 cells
(breast carcinoma cell line) to do the following experiments
because of its AP-2a–null expression and low–AP-2g ex-
pression. To demonstrate the effects of AP-2 on MDA MB-
231 cells, we used Ad-AP-2a and Ad-AP-2g to increase
AP-2a and AP-2g protein level, respectively. At 24 hours
after Ad-AP-2 infection, AP-2a and AP-2g expressions were
greatly increased in MDA MB-231 cells, in comparison with
untreated and Ad-Bgl II– infected cells [35]. Moreover, we
demonstrated that overexpressed AP-2a and AP-2g bound
AP-2 consensus-binding sites (Figure 1A) and were super-
shifted by their respectiveAP-2 antibodies (Figure 1A, lanes 7
and 11 ). MDA MB-231 is an aggressive growing cell line.
After introducing AP-2a or AP-2g expression by AP-2 ade-
noviral infection at 100 MOI, the growth rates of MDA
Figure 1. Ad-AP-2a and Ad-AP-2c adenovirus– infected MDA MB-231 cells
showed increased AP-2 DNA-binding activity and decreased clonogenic
survival. (A) MDA MB-231 cells were infected with increasing MOI of AP-2
adenoviruses, as indicated by ramps. Nuclear proteins were isolated
24 hours after infection. EMSAs were performed on nuclear extracts of both
MDA MB-231 cells to establish AP-2 DNA-binding activity to an AP-2
consensus-binding site in vitro. Radiolabeled AP-2 consensus-binding sites
were incubated with nuclear extracts under the following different conditions:
lane 1: probe only; lane 2: untreated MDA MB-231 nuclear extract; lane 3:
vector control Ad-Bgl II – treated cell extract; lanes 4 to 7: extracts from Ad-
AP-2a– treated cells with increasing MOI from 50, 100, 200, and 200; lanes 8
to 11: extracts from Ad-AP-2c– treated cells with increasing MOI from 50,
100, 200, and 200. To evaluate the specificity of this interaction, antibodies
specific to AP-2a (lane 7) and AP-2c (lane 11) were incubated with nuclear
extracts from 200 MOI of Ad-AP-2– infected MDA MB-231 cells. (B) MDA
MB-231 cells (2  106) were plated in 100-mm dishes and infected with
100 MOI of Ad-Bgl II or Ad-AP-2. After 24-hour infection, cells were
trypsinized and subcultured into 60-mm dishes at 500 cells/dish to determine
clonogenic fractions. Surviving fractions were normalized to untreated cells.
*P < .05 compared to untreated control cells and Ad-Bgl II – treated cells.
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MB-231 cells were significantly decreased [35], similar to
observations in the literature [20,33]. Moreover, their clono-
genic capabilities were lost in 100 MOI of Ad-AP-2–infected
MDA MB-231 cells, in comparison with untreated and vector
control– treated cells (Figure 1B).
Not Only AP-2a But Also AP-2c Overexpression Arrested
Cell Cycle and Elevated Levels of p21 Protein and mRNA
Cell cycle arrest is one of the mechanisms that could
lead to our observations. We performed BrdU incorporation
to monitor DNA synthesis during cell division and PI staining
for DNA content. Experiments were independently carried
out thrice. The cell fractions in G1/G0, S, and G2/M phases
were analyzed using CellQuest software (Becton Dickinson).
There was a dramatically increased cell number arrested
in G1/G0 phase and a significant decrease in the fraction of
cells in S phase after a 24-hour Ad-AP-2a or Ad-AP-2g
infection (Figure 2A).
It has been previously reported that p21 can be induced by
AP-2a and can inhibit cell growth [33]. Western blot analysis
and RT-PCR were performed to detect p21 expression after
either AP-2a or AP-2g expression. AP-2g caused an up-
regulation of both p21 mRNA and protein levels in a manner
similar to that in AP-2a. The magnitude of the p21 mRNA
increase was about the same in both Ad-AP-2a– and Ad-AP-
2g–infected cells (Figure 2, C and D).
Forced AP-2 Expression Significantly Decreased RB
Phosphorylation, Cyclin D1 mRNA and Protein Levels,
and E2F-Transactivating Activity
To gain further insight into the mechanism by which AP-2
causes cell cycle arrest, we proceeded to assess other
important factors involved in cell cycle progression. Cyclin
D1 is one of these factors because it promotes cell cycle
progression and is overexpressed in human breast cancers
[36–38]. In MDA MB-231 cells, forcing the overexpression
of AP-2a or AP-2g for 24 hours significantly reduced the
steady-state cyclin D1 mRNA level (Figure 3A). Cyclin D1
protein levels were also decreased by AP-2 not only in MDA
MB-231 cells but also in HCT116 (human colon carcinoma)
cells (Figure 3B). pRb is another major protein that regu-
lates cell cycle transitions from G1 to S phase. Moreover,
changes in p21 and cyclin D1 protein level can affect the
phosphorylation status of pRb [39]. Significantly decreased
phosphorylated Rb (Ser780, a cyclin D/CDK4–phosphory-
lated site) was detected by Western blot analysis in Ad-AP-
2a– and Ad-AP-2g–infected MDAMB-231 cells (Figure 3C).
However, there was no change in Rb mRNA levels (data
not shown). Another downstream effector in cell cycle pro-
gression is the family of E2F transcription factors. Elevated
E2F transactivation is a key event during G1–S cell cycle
transition. We used an E2F-responsive luciferase reporter,
which contains four E2F-binding sites fused to the firefly
luciferase gene, to measure E2F function after AP-2 over-
expression in MDA MB-231 cells. Relative luciferase ac-
tivity (firefly luciferase/renilla luciferase) was significantly
decreased in AP-2–expressing cells compared with vector
control– infected and untreated cells (Figure 3D).
Figure 2. Not only AP-2a but also AP-2c overexpression arrested cell cycle
and elevated p21 protein and mRNA levels in MDA MB-231 cells. (A) MDA
MB-231 cells were plated and infected with 100 MOI of various adenoviruses,
as indicated. After 24-hour incubation, cells were pulsed with BrdU and
labeled with BrdU antibody, and flow cytometry was performed. The fractions
of the cell population in different phases of the cell cycle were analyzed using
CellQuest Software. (B) MDA MB-231 cells were infected with various MOI
adenoviruses. Nuclear proteins and total RNA were isolated 24 hours after
infection. Western blot analyses were carried out to determine p21 protein
levels. -Actin was used as the control for loading and transfer. (C and D)
MDA MB-231 cells were treated as described in (B). Total mRNA was iso-
lated 24 hours after infection. Quantitative RT-PCR was used to determine
steady-state p21 mRNA levels. Results are expressed as mean ± SEM (n =
3). *P < .05 compared to untreated and vector control – treated mRNA
samples. yP < .05 compared to vector control – treated cells.
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Overexpression of AP-2a or AP-2c Failed to Cause G1
Arrest and to Inhibit BrdU Incorporation in p21 (/) Cells
p21, a well-known tumor suppressor, is upregulated by
AP-2a and AP-2g and may mediate, at least in part, the
observed AP-2– induced cell cycle arrest. To determine
whether AP-2 caused cell cycle arrest through p21, we
analyzed differences in cell cycle distribution and DNA syn-
thesis after AP-2 treatment in HCT116 parent (p21 wt) cells
and HCT116 p21 (/) cells. First, we confirmed whether
p21 protein was increased in HCT116 wt cells after AP-2
overexpression and whether there was no detectable p21
protein in either untreated and Ad-AP-2–treated HCT116
p21 (/) cells (Figure 4A). We found that BrdU incorpora-
tion, an indicator of S-phase DNA synthesis, was significantly
decreased in both Ad-AP-2a– and Ad-AP-2g–infected cells
compared with noninfected and Ad-Bgl II– infected HCT116
wt cells; however, there was no decrease observed in
HCT116 p21 (/) cells (Figure 4B). PI staining showed an
elevated fraction of cells in G1/G0 phase and a decreased
fraction of cells in S phase in both Ad-AP-2a– and Ad-AP-
2g–infected HCT116 parent cells compared with noninfected
and Ad-Bgl II– infected HCT116 parental cells (Figure 4C).
These results were consistent with those previously ob-
tained in the MDA MB-231 cell line (Figure 3). In contrast to
HCT116 parent cells, there was no decrease in S-phase frac-
tion and no increase in G1-phase fraction between vector
control– infected and Ad-AP-2a– and Ad-AP-2g–infected
HCT116 p21 (/) cells with the same MOI (Figure 4D).
Figure 3. Forced AP-2 expression significantly decreased Rb phosphorylation, cyclin D1 mRNA and protein levels, and E2F responsive promoter activity. (A) Cells
were infected with vector control or Ad-AP-2, as indicated. Total mRNA was harvested 24 hours after infection. Quantitative RT-PCR was used to determine cyclin
D1 mRNA level in MDA MB-231 cells. Results are expressed as mean ± SEM (n = 3). * P < .05 compared to untreated and vector control – treated mRNA sample.
(B) Cells were infected with 100 MOI of vector control or Ad-AP-2. Total cell lysates were harvested 24 hours after infection. Western blot analyses were conducted
to determine cyclin D1 protein levels in both MDA MB-231 and HCT116 wt cells. -Actin was used as a control for loading and transfer. (C) Cells were treated as
described above (B). Western blot analyses were conducted to determine pRb (S780) protein level in MDA MB-231 cells. (D) MDA MB-231 cells were infected with
Ad-Bgl II, Ad-AP-2a, or Ad-AP-2c at 100 MOI and transfected with 5 g of 4 E2F firefly luciferase reporter and 1 g of Cytomegalovirus renilla luciferase reporter,
as described in the Materials and Methods section. Total proteins from adherent cells were collected, and firefly luciferase activities were measured 24 hours after
infection. *P < .05 compared with control and vector control – treated cells.
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The general pattern of cell cycle distribution after Ad-AP-2
infection was not as pronounced in HCT116 p21 (/) cells
as in HCT116 wt cells. As to untreated HCT116 wt and p21
(/) cells, they displayed quite different cell cycle dis-
tributions, suggesting that knocking out p21 has effects on
elevating cell percentage in S phase while decreasing G1-
phase fraction (Figure 4D). It was noted that there were both
reduced G1/G0 fraction and enhanced G2/M percentage in
any adenovirally infected p21 (/) cell. The appearance of
G2 arrest might be due to the unavailability of p21-mediated
G1 arrest after adenoviral infection, which leads to both
arrests. Taken together, results from this series of experi-
ments indicated that p21 is a major player involved in AP-2–
induced cell cycle inhibition in human carcinoma cells.
Both AP-2a and AP-2c Bind to the p21 Proximal Promoter
Region In Vivo
It has been reported that AP-2a binds to p21 proximal
promoter and activates p21 expression [33]. AP-2a re-
combinant protein was demonstrated to bind DNA oligo-
nucleotides designed from the p21 promoter in vitro [33].
AP-2 family members, including AP-2g, can interact with the
same DNA consensus-binding sites and can activate many
genes. To determine whether AP-2a and AP-2g can bind to
the identified AP-2–binding sites on the p21 proximal pro-
moter in MDA MB-231 cells in vivo, we used ChIP. We
observed the enrichment of both AP-2a and AP-2g on the
p21 promoter in the respective adenovirus-infected cells
(Figure 5). Although the amount of input DNAwas equivalent,
only the ChIPDNA from the Ad-AP-2–infected cells yielded a
PCR product, indicating that AP-2 was bound to the p21
promoter in vivo.
AP-2 Expressing MDA MB-231 Cells Showed Less
Tumorigenicity, and Adenoviral AP-2 Infection Significantly
Delayed the Growth of Established Tumors In Vivo
To further investigate the tumor-suppressing role of
AP-2a and AP-2g in vivo, we monitored the tumor-forming
ability and growth rates of differently treated cells in nude
mice. In the first experiment, MDA MB-231 cells were in-
fected with 100 MOI of Ad-Bgl II or Ad-AP-2a or Ad-AP-2g
for 24 hours in vitro. Five million cells from different groups
were injected into each flank. The mice injected with un-
treated and vector control– treated cells were sacrificed
because they reached the maximum tumor size when the
tumor with Ad-AP-2a– or Ad-AP-2g–infected cells had just
started to grow. The recorded tumor initiation times of Ad-AP-
2a– or Ad-AP-2g– infected cells were significantly later
Figure 4. Overexpression of AP-2a or AP-2c failed to induce p21 protein G1 arrest and to inhibit BrdU incorporation in HCT116 p21 (/) cells. HCT116 parent and
p21 (/) cells were infected with 100 MOI of vector control or Ad-AP-2 for 24 hours. (A) Total proteins were isolated, and Western blot analysis was carried out to
detect p21 protein level. -Actin was used as control for loading and transfer. (B) Cells were pulsed with BrdU and labeled with BrdU antibody. PI staining was used
to detect total DNA content. Flow cytometry was carried out. Quantitative BrdU FITC level was calculated for every cell group. *P < .05 compared to untreated
control cells and vector control – treated cells. Fractions of cells are shown as histograms of HCT116 wt cells (C) and HCT116 p21 (/) cells (D). *P < .05
compared to untreated control cells. yP < .05 compared to vector control – treated cells.
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than those of untreated and vector control– treated cells
(Figure 6A). The survival of animals was greatly improved
in animals bearing Ad-AP-2–infected cells (data not shown).
Compared with both controls, it took approximately 1 month
longer to reach the same tumor size for Ad-AP-2–infected
tumors. To determine whether there was an effective ther-
apeutic response in establishing tumors treated with Ad-
AP-2 adenoviruses, we injected 1  109 pfu into each tumor
every 5 days (thrice in total) when the tumors were roughly
3 to 4 mm in diameter. We monitored tumor growth and
animal survival after the first injection. The tumors treated
with the adenovirus expressing either AP-2a or AP-2g grew
more slowly compared with vector control– treated and un-
treated tumors (Figure 6B). Better survival fractions were
observed in AP-2–treated animals (data not shown).
Discussion
There are many proteins and redundant pathways to pro-
tect cells from tumor formation. Besides p53, Rb, p16, and
others, AP-2a and AP-2g are also implicated in tumor
suppression. AP-2a and AP-2g, two members of the AP-2
family, are transcription factors with high homology to each
other. AP-2a and AP-2g were shown to have some similar
behaviors, including interaction with p53 [22,40], suscepti-
bility to tumor necrosis factor-a downregulation [21], and
neural development [4,8,9,41]. It has been reported that
the AP-2a transcription factor can upregulate p21, arrest cell
cycle progression, induce apoptosis, and promote tumor
death [20,33,42]. Moreover, both AP-2a and AP-2g are
transcriptional targets of wt p53 [35]. Therefore, it has been
suggested that not only AP-2a but also AP-2g have tumor-
suppressor activities. In these studies, we have identified
both AP-2a and AP-2g as transcription factors that inhibit
MDA MB-231 cell growth in vivo and in vitro. Both AP-2
proteins can upregulate p21 mRNA and protein levels, arrest
cell cycle in G1/G0 phase, decrease tumor cell clonogenicity,
downregulate cyclin D1 mRNA and protein levels, decrease
Rb phosphorylation, and attenuate E2F function. Cell cycle
arrest caused by AP-2 expression is attributed to tumor cell
growth inhibition in vivo and in vitro. We further demon-
strated that p21 is the mediator, at least in part, between
AP-2 and cell cycle regulation by using HCT116 parental
and p21 (/) cells. The failure to induce cell cycle arrest in
G1/G0 phase and to decrease BrdU incorporation by AP-2 in
HCT116 p21 (/) cells revealed the importance of p21 as
an AP-2 downstream target in cell cycle modulation. AP-2a
and AP-2g appear to act in the same fashion in regard to cell
cycle regulation and p21 elevation.
AP-2a expression predicts survival in melanoma and
breast cancer [27,42]. Some in vivo studies showed elevated
melanoma growth by inactivating AP-2a expression [42].
Here, we demonstrated decreased tumorigenicity of MDA
MB-231 cells in nude mice after adenoviral AP-2a or AP-2g
infection, and corresponding animal survival was greatly
improved. To determine the role of AP-2 in cancer treatment,
we infected established tumors with the same doses of
adenoviruses, and decreased tumor growth was observed
in AP-2–treated groups in comparison with untreated and
vector control– treated groups. Thus, it would be desirable
to develop therapeutic strategies aimed at breast cancer
based on targeted reexpression of AP-2a and/or AP-2g.
Figure 5. Both AP-2a and AP-2c bind to p21 proximal promoter in vivo. MDA
MB-231 cells were infected with vector control, Ad-AP-2a, or Ad-AP-2c at
100 MOI. Twenty-four hours after infection, AP-2a and AP-2c antibodies were
used to immunoprecipitate protein-bound DNA. An equivalent amount of
genomic DNA without immunoprecipitation was used as input control.
Standard PCR was carried out to determine the extent of AP-2 binding to
the p21 proximal promoter region illustrated in Zeng et al. [33].
Figure 6. AP-2–expressing MDA MB-231 cells showed less tumorigenicity,
and adenoviral AP-2 infection significantly delayed established tumor growth
in vivo. (A) MDA MB-231 cells were infected with 100 MOI of vector control or
Ad-AP-2 in vitro for 24 hours before injection. Under sterile conditions, 7- to 8-
week-old nude mice were injected subcutaneously (day 0). Tumor sizes were
measured and calculated according to the description in the Materials and
Methods section. For statistical analysis, time of tumor initiation was defined
as the first day on which tumor volume exceeded 10 mm3. (B) Under sterile
conditions, 7- to 8-week-old nude mice were injected subcutaneously with
MDA MB-231 cells. When the average diameter reached 3 to 4 mm, animals
were grouped to achieve the same average tumor volume per group. Then
1  109 pfu of indicated adenoviruses was injected into each tumor (day 0).
Adenoviral injections (a total of three injections) were performed every 5 days.
Animals were sacrificed when any tumor reached 1000 mm3 in either flank.
*P < .05 compared to untreated and Ad-Bgl II – treated groups.
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Based on our findings, we propose a model for the
mechanisms involved in AP-2–induced cell growth inhibition
(Figure 7). In the presence of wt AP-2a or AP-2g, p21 mRNA
and proteins are expressed, whereas cyclin D1 is repressed.
Consequent pRb hypophosporylation leads to E2F inactiva-
tion, which facilitates cell cycle arrest. When AP-2a or AP-2g
expression is lost during tumor formation, p21 expression is
decreased and cyclin D1 becomes more actively expressed.
The subsequent phosphorylation of pRb and activation of
E2F promote cell proliferation and tumor formation.
In the current study, the mechanisms involved in AP-2–
induced p21 upregulation were investigated. A previous
study by Zeng et al. [33] identified a 20-bp sequence consist-
ing of three AP-2–binding sites located at the proximal p21
promoter as AP-2a–responsive elements. Because both
AP-2a and AP-2g bind to the same consensus-binding sites,
we demonstrated that both AP-2 can bind to the p21 proxi-
mal promoter in vivo. It is reasonable that AP-2a and AP-2g
work together to upregulate p21. Our previous study showed
that AP-2a and AP-2g act synergistically to transactivate
a 12 AP-2–responsive CAT reporter [35]. Whether AP-2
family members work synergistically to regulate p21 and cell
cycle control needs further investigation.
Besides the tumor-suppressor effects of AP-2, it also
plays a very important and indispensable role in development
and differentiation [43,44]. AP-2a knockout mice have lethal
defects and usually die at birth [43]. Moreover, some differ-
entiated tissues retain AP-2a expression after development.
It is suggested that AP-2a keep these cells from uncontrolled
division after an appropriate physiological growth stimulus.
Different members from the AP-2 family may play variable
roles in different stages throughout life.
Future work will seek to identify different functions among
AP-2 family members and further examine whether both
AP-2g with AP-2a can work synergistically as therapeutic
genes to improve cancer therapy or survival. Overall, this
study compared AP-2g with AP-2a in suppressing certain
aspects of the malignant phenotype. Our results indicate
that AP-2g binds to the p21 promoter in vivo, activates its
expression, and thus causally participates in cell cycle
arrest in human carcinoma cells derived from the breast
and the colon. Our results further suggest that both AP-2g
with AP-2a can inhibit tumor growth and therefore serve as
tumor suppressors.
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